form8k-83320_cnmd.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): March 31, 2007
CONMED
CORPORATION
(Exact
name of registrant as specified in its charter)
|
New
York
|
0-16093
|
16-0977505
|
|
(State
or other jurisdiction of
|
(Commission
|
(I.R.S.
Employer
|
|
incorporation
or organization)
|
File
Number)
|
Identification
No.)
|
525
French Road
Utica,
New York 13502
(Address
of principal executive offices, including zip code)
(315)
797-8375
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligations of the registrant under any of the following
provisions (See General Instruction A.2 below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 7.01
Regulation FD Disclosure
As
disclosed in the Registrant's Annual Report on Form 10-K for the year ended
December 31, 2006, in November 2003, CONMED Corporation (the "Company")
commenced litigation against Johnson & Johnson and several of its
subsidiaries, including Ethicon, Inc. for violations of federal and state
antitrust laws. The lawsuit claims that Johnson & Johnson engaged in illegal
and anticompetitive conduct with respect to sales of product used in endoscopic
surgery, resulting in higher prices to consumers and the exclusion of
competition. The Company had sought relief which includes an injunction
restraining Johnson & Johnson from continuing its anticompetitive practice
as well as receiving the maximum amount of damages allowed by law.
On
March
31, 2007, CONMED and Johnson & Johnson settled the
litigation. CONMED will receive a payment of $11.0 million from
Johnson & Johnson and we have agreed to terminate the
lawsuit. During the litigation, Johnson & Johnson represented
that the marketing practices which gave rise to the litigation have been
altered
with respect to CONMED.
After
deducting estimated legal and other related costs, CONMED will record a pre-tax
gain in the range of $6.3 million to $6.8 million.
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
CONMED
CORPORATION
|
| |
(Registrant)
|
| |
|
|
| |
|
|
| |
By:
|
Robert
D. Shallish, Jr.
|
| |
|
Vice
President – Finance and
|
| |
|
Chief
Financial Officer
|
Date:
April 4, 2007